Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Conditions
Non-Small Cell Lung Cancer (NSCLC) · Colorectal Cancer · Pancreatic Ductal Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City of Hope, Duarte, California, United States
UC IRVINE Health, Orange, California, United States
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
Stanford Cancer Institute, Stanford, California, United States
University of Colorado Cancer Center, Aurora, Colorado, United States
Florida Cancer Specialists, Sarasota, Florida, United States
Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Henry Ford Cancer, Detroit, Michigan, United States
START Midwest, Grand Rapids, Michigan, United States
Columbia University, New York, New York, United States
NYU Langone Health, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of Oklahoma, Oklahoma City, Oklahoma, United States
Sarah Cannon Research Institue, Nashville, Tennessee, United States
Mary Crowley Cancer Research, Dallas, Texas, United States
MD Anderson, Houston, Texas, United States
NEXT Dallas, Irving, Texas, United States
NEXT Oncology San Antonio, San Antonio, Texas, United States
START Texas, San Antonio, Texas, United States
NEXT Oncology Virginia, Fairfax, Virginia, United States
West Cancer Institute, Angers, France
Institut Bergonie, Bordeaux, France
Hospital Louise Pradel, Bron, France
Oscar Lambret Center of Lillle, Lille, France
Centre Leon Berard, Lyon, France
Cancer Institute of Montpellier, Montpellier, France
CHU Nantes, Nantes, France
Institute of Cancer of Strasbourg, Strasbourg, France
Universitäts Klinikum Köln, Cologne, Germany
Klinikum Esslingen GmbH, Esslingen am Neckar, Germany
Krankenhaus Bethanien Moers, Moers, Germany
Klinkum Nurnberg Paracelsus Medical Unviersity, Nuremberg, Germany
Department of Medical Oncology - Azienda Ospedaliero Uniersitaria delle Marche, Ancona, Italy
Centro Di Riferimento Oncologico, Aviano, Italy
Institute Romagnolo per lo Studio Tumori, Meldola, Italy
Niguarda Cancer Center, Milan, Italy
Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy
San Luigi Hospital, Orbassano, Italy
AUSL Romagna - S.M. delle Croci Hospital, Ravenna, Italy
Netherlands Cancer Institute Antoni van Leeuwenhoek, Amsterdam, Netherlands
Pan American Center for Oncology Trials, San Juan, Puerto Rico
START Barcelona - Hospital HM Nou Delfos, Barcelona, Spain
Institut Catala d'Oncologia Hospital, Barcelona, Spain
University Clinic of Navarra, Madrid, Spain
Fundacion MD Anderson Cancer Center, Madrid, Spain
START Madrid, Madrid, Spain
Hospital Universitario 12 de Octubre, Madrid, Spain
NEXT Oncology - Quirónsalud Madrid University Hospital, Madrid, Spain
University Clinic of Navarra, Pamplona, Spain
Hospital Universitario Virgen Macarena, Seville, Spain
La Fe University and Polytechnic Hospital, Valencia, Spain
Hospital Universitario Miguel Servet, Zaragoza, Spain
Study leads
Revolution Medicines, Inc.
Study Director
Revolution Medicines, Inc.